Prescribing (n=39) | Review (n=44) | TAU (n=42) | |
---|---|---|---|
SF-6D at baseline, mean (SD) | 0.6349 (0.1336) | 0.6173 (0.1431) | 0.6077 (0.1140) |
SF-6D at 3 months, mean (SD) | 0.6428 (0.1396) | 0.6411 (0.1469) | 0.6226 (0.1405) |
SF-6D at 6 months, mean (SD) | 0.6500 (0.1462) | 0.6291 (0.1471) | 0.6105 (0.1336) |
Unadjusted total QALYs, mean (SD) | 0.3213 (0.0659) | 0.3161 (0.0684) | 0.3079 (0.0606) |
Adjusted difference in total QALYs versus TAU, mean (95% CI)* | 0.0069 (−0.0091 to 0.0229) | 0.0097 (−0.0054 to 0.0248) |
The number of patients with data on all these baseline variables: prescribing (n=35); review (n=39), TAU (n=34).
*Estimates from regression analyses with adjustment for differences in baseline costs, baseline SF-6D health utility score and other patient characteristics (age, sex, marital status, work status, education, income, baseline CPG—intensity).
QALYs, quality-adjusted life years; SF-6D, short form six-dimension; TAU, treatment as usual.